Diclo P

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Diclo P

Property Description
Active Ingredient Diclofenac Sodium or Diclofenac Potassium
Form Tablets, Gels, Suppositories, or Injectable Solutions
Pharmacological Class Nonsteroidal Anti-inflammatory Drug (NSAID)
General Purpose Symptomatic relief of pain, inflammation, and fever
Origin Synthetic Compound

What Type of Medicine is Diclo P?

Diclofenac (the active component in Diclo P) is a synthetic compound classified as a Nonsteroidal Anti-inflammatory Drug (NSAID). This places it in the major drug class recognized for its combined analgesic, anti-inflammatory, and antipyretic capabilities. Diclofenac is used for reducing pain and swelling through its mechanism as an NSAID. This means the medicine is generally intended to ease discomfort by interrupting the body's natural inflammatory response. Diclofenac is chemically defined as a phenylacetic acid derivative, distinguishing it from older NSAIDs like aspirin and confirming its role as an agent against inflammatory processes.


Composition and Available Forms of Diclo P

The preparation Diclo P contains Diclofenac as its single active ingredient, typically presented as the sodium or potassium salt. This single-entity composition is formulated into several dosage forms designed to target both localized and systemic conditions. These forms include conventional and specialized oral tablets (such as enteric-coated or extended-release versions), topical gels, suppositories, and injectable solutions. This variety in preparation allows for different routes of administration, including oral, topical (dermal), and intramuscular delivery. Diclofenac is widely utilized for managing common pain and inflammation symptoms.


General Purpose and Physiological Action

The general purpose of Diclofenac is to provide symptomatic relief by reducing the physiological drivers of discomfort: pain, inflammation, and fever. Diclofenac achieves this by acting as a Cyclooxygenase (COX) inhibitor, which blocks pain and inflammation signals throughout the body. By inhibiting the COX enzymes, the drug prevents the production of prostaglandins, which are the chemical messengers responsible for initiating these symptoms. A typical use scenario involves its application for relieving the general stiffness associated with minor muscular aches. In essence, it provides relief by targeting the root mechanism of the inflammatory response.

Regulatory References

  1. NIH: Diclofenac (StatPearls)

What side effects are possible with Diclo P?

Possible Side Effects and Safety Information

The safety profile of Diclofenac (Diclo P) is structurally defined by how adverse reactions are officially classified and documented in regulatory prescribing information. All possible effects are categorized by System-Organ Class (SOC) and assigned a frequency rating (e.g., Common, Rare).


Frequency-Classified Adverse Reactions

Classification Examples of Officially Listed Reactions
Common (ge 1/100 to <1/10) Gastrointestinal disturbances (such as nausea, vomiting, abdominal pain), headache, dizziness, and elevated liver enzyme values.
Rare (ge 1/10,000 to <1/1,000) Gastrointestinal bleeding, ulceration, hepatitis, and severe hypersensitivity reactions.
Very Rare (< 1/10,000) Serious thrombotic events, severe skin reactions (e.g., SJS, TEN), and acute renal failure.

Designated Serious Adverse Reactions

Regulatory documents emphasize specific, high-risk events. These include Cardiovascular Thrombotic Events (such as Myocardial Infarction and Stroke), which may increase with duration of use and higher doses. The risk of Gastrointestinal Bleeding, Ulceration, or Perforation is also highlighted, which can occur at any time during treatment.

Safety Restrictions and Special Populations

Diclofenac is formally Contraindicated in specific clinical scenarios, notably for the treatment of perioperative pain in the setting of Coronary Artery Bypass Graft (CABG) surgery and for patients with established Congestive Heart Failure (NYHA class II–IV). Older Adults are noted to be at a greater risk for serious gastrointestinal events. Systemic use must be avoided during the third trimester of pregnancy due to risks related to the fetal cardiovascular system.

Overdose and Emergency Response

Overdose and When to Seek Help

Taking more than the recommended dose of Diclo P (which contains diclofenac, a Nonsteroidal Anti-inflammatory Drug or NSAID, and paracetamol/acetaminophen) can lead to serious adverse effects. An overdose requires immediate medical attention, even if you do not feel ill right away, because the effects of the paracetamol component, particularly liver damage, may not become apparent for 24 to 72 hours.

Symptoms of Diclo P Overdose

Symptoms following an overdose can be varied, presenting with gastrointestinal, renal, and neurological signs. Common initial symptoms may include:

  • Gastrointestinal: Nausea, vomiting, stomach pain, or abdominal bleeding (indicated by bloody, black, or tarry stools).
  • Neurological: Drowsiness, dizziness, unsteadiness, or headache. Severe cases may result in confusion, seizures, or coma.
  • Other: Ringing in the ears (tinnitus), little or no urine output, or rapid/irregular heartbeat.

When to Seek Immediate Medical Help

Call your local emergency number or poison control center immediately if you or someone else has taken more than the prescribed amount of Diclo P. Do not wait for symptoms to appear.

Emergency medical care is critical if any severe symptoms develop, such as difficulty breathing, severe vomiting (especially with blood or material resembling coffee grounds), extreme drowsiness, confusion, loss of consciousness, or signs of liver damage like yellowing of the skin or eyes (jaundice).

Treatment for overdose is supportive and may involve hospital monitoring, administration of activated charcoal to prevent absorption, and specific antidotes (like N-acetylcysteine) for the paracetamol component to prevent liver toxicity.

Therapeutic Uses of Diclo P

What Diclo P Treats: Main Uses and Benefits

Diclo P provides supportive symptomatic relief by addressing the core drivers of patient discomfort: pain, inflammation, and fever. It is generally used across various clinical settings where symptoms that interfere with daily functioning create noticeable physiological strain. It is used in the treatment and management of acute and chronic pain associated with inflammatory processes.

The medicine is commonly used to help with conditions characterized by periods of heightened symptoms, including osteoarthritis, rheumatoid arthritis, acute gout, soft tissue injuries, acute migraine attacks, and primary dysmenorrhea. It is also relevant in clinical scenarios such as post-surgical recovery and following trauma.

It offers supportive therapeutic benefit by assisting with the discomfort of these manifestations, which may contribute to improved day-to-day comfort.

“This medication is applied in situations where additional management of discomfort is required to help maintain a sense of stability.”

This supportive approach assists with managing symptom clusters that may become intense or disruptive, helping patients cope more steadily with difficult episodes.

Quick Fact: Support for Symptoms related to Pain and Inflammation
Diclo P may be part of symptomatic management in situations involving distressing joint pain, swelling, and stiffness, and for symptoms associated with acute episodic pain like migraine and colic.

Regulatory References

  1. NIH StatPearls overview

Eligibility and Restrictions for Use

Eligibility to Use Diclo P (Diclofenac)

Official regulatory sources specify clear restrictions on who can use Diclo P, a non-steroidal anti-inflammatory drug (NSAID).

Classification Description
Contraindicated (Must NOT Use) Individuals with a known allergy to diclofenac, aspirin, or other NSAIDs (due to risk of asthma, urticaria, or anaphylaxis). Patients with established severe congestive heart failure (NYHA class II-IV), ischemic heart disease, peripheral arterial disease, or cerebrovascular disease. Use is also prohibited for pain relief immediately before or after Coronary Artery Bypass Graft (CABG) surgery. Systemic formulations are contraindicated after 30 weeks of pregnancy and in cases of severe, uncontrolled kidney or liver disease.
Restricted/Caution (Use Only After Review) Use is not recommended in patients with a history of GI bleeding or ulcers related to NSAID use, advanced renal disease, or a recent myocardial infarction (MI), unless the benefits outweigh the risks. Older adults may require caution due to higher risk of kidney, heart, and GI issues. Breastfeeding is not recommended as the drug passes into milk.
Age Limits Oral/systemic use is generally established in adults. Specific age limits exist for certain formulations; for example, some oral products are approved for pediatric patients 12 years and older, while certain topical products have limits as low as 6 years and older (depending on the product and indication).

What should I know about interactions with other medicines?

Diclo P Interactions with other medicines and products: Official Regulatory Information

The interaction profile of Diclofenac (Diclo P) is officially documented across several regulatory domains, imposing specific constraints on co-administration with other medicines and products.

Contraindicated and High-Risk Combinations

  • Procedural Contraindication: Use is formally contraindicated for managing perioperative pain in the setting of Coronary Artery Bypass Graft (CABG) surgery [FDA Label].
  • Additive Toxic Risk: Co-administration with Aspirin at analgesic doses or other NSAIDs is generally not recommended due to the increased risk of serious gastrointestinal adverse events, including bleeding [FDA/SmPC].

Interactions Affecting Drug Exposure

Mechanism / Substance Classification & Outcome (as documented)
Anticoagulants (e.g., Warfarin) Additive Risk: Causes a synergistic increase in the risk of serious gastrointestinal bleeding.
Voriconazole (CYP Inhibitor) Exposure Increase: Significantly increases Diclofenac's plasma concentration (Cmax and AUC increased) [FDA Label].
Lithium and Digoxin Reduced Clearance: Diclofenac can increase the serum concentration and prolong the half-life of these medicines.
Methotrexate Increased Toxicity: Enhances Methotrexate's toxicity due to reduced renal clearance, which can be linked to competition for organic anion transporters (OATs).

Pharmacodynamic and Contextual Restrictions

  • Antagonistic Effect: Diclofenac may diminish the anti-hypertensive effect of ACE Inhibitors, ARBs, or Diuretics (thiazide and loop types) [FDA Label].
  • Specific Populations: The interaction with ACE Inhibitors/ARBs, which can result in the deterioration of renal function, is specifically highlighted as being more clinically significant in the elderly, volume-depleted, or renally impaired population [FDA Label].
  • Dietary Factors: Alcohol consumption is noted to increase the risk of serious gastrointestinal bleeding. Certain Diclofenac capsule formulations are contraindicated in patients with a known allergy to bovine protein due to ingredients [FDA Label].

The overall regulatory profile structures the constraints based on the severity of the interaction, ranging from formal prohibition (CABG, other NSAIDs) to clear documentation of pharmacokinetic and pharmacodynamic consequences with specific medication classes.

Mechanism of Action

How Diclo P Works

The core mechanism of Diclofenac (the "Diclo" component) is centered on the selective modulation of enzyme activity within key signaling pathways, thereby modulating excessive signaling within defined pathways.

Enzyme Target: Cyclooxygenase (COX) Inhibition

Its action targets the Cyclooxygenase (COX) enzyme system, which is a critical biological target that initiates the process of generating inflammatory and pain-sensitizing substances. The inhibition of this enzyme limits the molecular sequence that leads to downstream signaling.

Pathway Effect: Prostaglandin Synthesis Modulation

This immediate consequence interrupts the eicosanoid pathway. By suppressing the synthesis of lipid mediators such as prostaglandins, the drug alters signaling dynamics in inflammatory and nociceptive pathways, leading to a diminished level of mediator activity.

Physiological Consequence: Modulation of Signaling Balance

The resulting molecular changes alter the balance of signaling mediators, which manifests as a modification of the threshold for peripheral neuron activation. This action influences core mechanisms that regulate specific signals within the pathways, influencing the subsequent regulatory feedback mechanisms.

Dosage and Administration Information

How to Use Diclo P: Administration Guidelines

Administration methods for Diclo P (Diclofenac) vary across various dosage forms and delivery methods. A general principle for use is the application of the lowest effective dosage for the shortest possible duration.


General Dosing and Timing

Form / Route Standard Dosing Range Key Instructions
Oral (Delayed-Release) Total daily doses up to 150 mg or 200 mg, divided. May be taken without regard to food; must be swallowed whole.
Oral (Immediate-Release) Acute use often 50 mg per dose, up to three times daily. Typically taken on an empty stomach to maximize absorption.
Topical Gel 1% 2 g or 4 g per affected joint, four times daily (q.i.d.). Applied using a dosing card; total daily dose should not exceed 32 g.

Administration Requirements

Diclofenac is available for oral (systemic), topical (dermal), rectal, and parenteral administration.

For Oral administration, formulations such as Delayed-Release tablets are not to be crushed, chewed, or broken to maintain their intended release profile. For certain acute forms, such as the oral solution powder, it is mixed with 1 to 2 ounces of water and consumed immediately.

For Topical use, the product is applied to clean, dry skin. Hands should be washed completely after application, unless the hands are the site being treated.

Population-Specific Use

For older adults, treatment is commonly initiated at the lowest possible effective dose. Patients with hepatic impairment may also require reduced starting doses due to the role of the liver in drug elimination.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Diclo P


Evidence Base for Osteoarthritis (OA) and Chronic Joint Pain

Research has explored how patient-reported outcomes describing perceived discomfort evolve in conditions such as osteoarthritis (OA). The primary research base consists of Randomized Controlled Trials (RCTs) and comprehensive meta-analyses. These studies included adults and older adults with a diagnosis of OA, focusing on the knee and hand. Research examined the use of both oral tablets and topical gels or solutions.

Researchers primarily monitored outcomes related to physical discomfort, specifically patient-reported outcomes describing perceived discomfort and outcomes reflecting daily functioning or activity level. Findings describe patterns observed in the studies where participants reported changes measured during the study period in these outcomes.

Follow-up durations were limited in most high-quality trials. There is limited information for long-term outcomes regarding the sustained symptomatic patterns beyond roughly 12 weeks of continuous use. Furthermore, studies focusing on topical formulations predominantly involved the knee and hand, meaning results apply only to the populations studied and specific joint sites.


Evidence Base for Rheumatoid Arthritis and Other Systemic Inflammation

For managing the pain and inflammation associated with long-term conditions like rheumatoid arthritis (RA) and ankylosing spondylitis, Diclo P was evaluated in a number of RCTs and subsequent systematic reviews. The research monitored outcomes linked to inflammatory or irritative states, such as changes in the count of swollen and tender joints. Studies generally describe patterns related to outcomes related to physical discomfort in the observed populations.

It is important to understand that the research for RA and ankylosing spondylitis was studied for symptomatic relief only. The evidence does not determine whether this medicine affects the long-term progression or underlying severity of the disease itself. Furthermore, specialized studies focused on comorbidity-defined groups within the RA population are less extensive.


Evidence Gaps and Research Uncertainty

Scientific reviews highlight several areas where research is ongoing or where certainty remains low. A major limitation is the limited availability of high-quality evidence concerning long-term symptomatic patterns for chronic pain conditions. Another gap is the consistency of evidence in the pediatric population, where data for certain groups remain insufficient.

Frequently Asked Questions (FAQ)

Common questions about Diclo P (FAQ)


Q: Is Diclo P the same kind of drug as ibuprofen?

Official classifications describe both Diclo P (Diclofenac) and ibuprofen as Nonsteroidal Anti-inflammatory Drugs (NSAIDs). This means they belong to the same major pharmacological class, sharing a common mechanism of action. However, regulatory sources confirm they are chemically defined as distinct compounds.


Q: Does Diclo P cause drowsiness or fatigue?

According to official regulatory documents, adverse effects such as fatigue and somnolence (drowsiness) have been reported in the post-marketing or clinical trial data for Diclofenac. While these are not listed as the most common side effects, they are documented possibilities.


Q: Are there any long-term side effects associated with Diclo P?

Regulatory agencies issue warnings indicating that the risk of serious side effects, especially those affecting the heart and blood vessels, may increase with a longer duration of use. Because of these findings, official guidance emphasizes the importance of using the lowest effective dosage for the shortest possible duration.


Q: What does 'contraindicated' mean in relation to Diclo P?

The term contraindicated is used in official regulatory documents to signify situations where the medicine must not be used. This prohibition is based on medical evidence that shows using the medicine under certain conditions, like having a specific illness or being in a particular stage of pregnancy, could cause harm.


Q: Is there a maximum time frame for how long Diclo P should be used?

Official instructions prioritize using the medicine for the shortest possible duration necessary to achieve the desired outcome. While this general principle is always applied, some regulatory labeling for specific forms or indications may define explicit maximum treatment durations.


Q: What is Diclo P's official classification or scheduling (e.g., controlled substance)?

Diclo P (Diclofenac) is generally classified as a Nonsteroidal Anti-inflammatory Drug (NSAID) by major regulatory bodies. It is not designated as a controlled substance at the federal level in major regions, although its availability, whether prescription-only or non-prescription, can vary by country and specific formulation.


Q: What are the signs of a serious, but rare, side effect from Diclo P?

Official patient information describes the importance of recognizing specific physical signs related to major adverse events. These signs can include unexpected swelling, new skin rashes, sudden chest pain, or symptoms indicating internal bleeding, such as black, tarry stools or vomiting material that looks like coffee grounds. If these occur, official information indicates that immediate medical attention is required.


Q: Can Diclo P affect the results of lab tests?

Official documentation notes that the medicine can cause certain lab values to change. The most commonly reported change is elevated liver enzyme values. It may also affect the results of other tests, such as those used to monitor kidney function or blood clotting (coagulation), which are often monitored during its use.


Q: Can you take Diclo P if you have high blood pressure?

Regulatory documents advise caution when the medicine is used in people with existing hypertension (high blood pressure). The official warning is that Diclofenac may cause new hypertension or worsen existing high blood pressure.


Q: How long does it typically take before Diclo P starts working?

For certain oral forms of Diclo P, the time it takes to reach maximum concentration in the blood is typically between 30 to 60 minutes after use. This period often corresponds to the initial onset of the noticeable effect.


Q: How long does the effect of a single use of Diclo P usually last?

The clinical effects of a single use are linked to the recommended dosing frequency outlined in official guidelines, such as being taken up to three times daily. While the medicine’s chemical half-life in the bloodstream is short (typically 1 to 2 hours), the overall symptomatic relief may last longer.


Q: Can Diclo P be taken if I am using an antidepressant?

Official documents advise caution when Diclo P is used concurrently with specific types of antidepressants known as Selective Serotonin Reuptake Inhibitors (SSRIs). This is due to an officially recognized potential for an increased risk of bleeding when the two types of medicines are combined.


Q: Can Diclo P cause difficulty sleeping?

Official labeling for Diclofenac has noted cases of insomnia, or difficulty sleeping, as a documented adverse reaction. This effect is generally listed among the less common side effects reported from regulatory data.


Q: Does Diclo P have an effect on blood sugar levels?

Official regulatory text has documented that this medicine may affect blood sugar control in certain individuals. This effect is particularly noted in patients who are also using specific oral antidiabetic medicines.


Q: Is it possible to become dependent on Diclo P?

As a Nonsteroidal Anti-inflammatory Drug (NSAID), Diclofenac is not generally classified as a medicine with a potential for dependence. Regulatory documents do not recognize it as habit-forming.


Q: Does using Diclo P make you more sensitive to the sun?

Regulatory information advises that this medicine may cause your skin to be more sensitive to sunlight, a condition known as photosensitivity. Official guidelines sometimes include recommendations regarding limiting sun exposure while using Diclofenac.


Q: Can Diclo P cause changes in mood or anxiety?

Official labeling has documented rare adverse effects that may include changes in mood, depression, or feelings of anxiety. These events are noted in regulatory data but are not frequently reported.


Q: Is it normal if I don't feel Diclo P working immediately?

Since the medicine requires time, typically 30 to 60 minutes, to reach its maximum concentration in the blood, it is common not to feel the effect immediately upon use. This waiting period is consistent with the drug’s intended absorption and action profile.

How should Diclo P be stored and disposed of?

How to Store and Dispose of Diclo P

The official storage and disposal requirements for Diclo P (diclofenac) are strictly defined by regulatory labeling to maintain product stability and safety.

Storage Requirements

Oral forms must be stored at controlled room temperature (20 C to 25 C), with excursions permitted up to 30 C. The medicine must be kept in the original container and often tightly closed to protect it from moisture and light. Specific forms, like topical gels, carry the constraint: Do not freeze.

Safety and Disposal

A mandatory requirement is to keep Diclo P out of the sight and reach of children.

Disposal instructions state that unused or expired product must not be thrown away via wastewater or household waste and should instead be handled according to local pharmaceutical waste regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Diclo P found in:

A-Z Index: